Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBiosimilars make an important contribution to the sustainability of health systems by providing alternatives to originator biologic products once those products no longer have patent or other forms of market exclusivity.
Across Europe, the level of competition among biosimilars differs widely by country and by molecule, as does their impact on pricing, and the extent of their use by patients. Much of this variability can be linked to differences in policy elements across health systems that contribute to sustainable market conditions for biosimilars.
This set of scorecards maps these elements per country and measures the overall contribution of biosimilars to the health system. They are a useful tool to help countries assess their current performance and identify areas for improvement.
European healthcare systems share commonalities but have specific differences which mean that policy scores should not be compared directly to each other. Therefore, ‘The Sustainable Market’ scorecard has been developed which acts as a gold-standard market by which comparisons can be made. This avoids misinterpretation or inaccurate comparison of countries.
The European Country Biosimilar Scorecards and Appendix, which provides detailed methodologies and explanations of the metrics and assessments incorporated into the scorecards, were developed by the IQVIA Institute for Human Data Science with funding from the Biosimilar Medicines Group, a sector group of Medicines for Europe.
To get the most value, it is recommended to download the Methodology Appendix and the Sustainable Market Scorecard along with the individual country scorecards.
This appendix provides the methodologies and explanations of the metrics and assessments incorporated into the European country biosimilar scorecards. It describes each part of the scorecard, the approach, and sources used for the various assessments.
This scorecard is a representation of how the ideal market place should perform to ensure optimal market sustainability and patient-focus. It provides the gold-standard policies to which country scorecards can compare themselves.
To get the most value, it is recommended to download the Methodology Appendix and the Sustainable Market Scorecard along with the individual country scorecards.
To get the most value, it is recommended to download the Methodology Appendix and the Sustainable Market Scorecard along with the individual country scorecards.